MX2024004766A - Tratamiento de irritabilidad en sujetos con trastornos de espectro autista con ansiedad y/o evitación social de moderada a severa. - Google Patents

Tratamiento de irritabilidad en sujetos con trastornos de espectro autista con ansiedad y/o evitación social de moderada a severa.

Info

Publication number
MX2024004766A
MX2024004766A MX2024004766A MX2024004766A MX2024004766A MX 2024004766 A MX2024004766 A MX 2024004766A MX 2024004766 A MX2024004766 A MX 2024004766A MX 2024004766 A MX2024004766 A MX 2024004766A MX 2024004766 A MX2024004766 A MX 2024004766A
Authority
MX
Mexico
Prior art keywords
irritability
subjects
moderate
autism spectrum
treatment
Prior art date
Application number
MX2024004766A
Other languages
English (en)
Spanish (es)
Inventor
Joseph Palumbo
Stephen V O''quinn
Original Assignee
Zynerba Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zynerba Pharmaceuticals Inc filed Critical Zynerba Pharmaceuticals Inc
Publication of MX2024004766A publication Critical patent/MX2024004766A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2024004766A 2021-10-22 2022-10-20 Tratamiento de irritabilidad en sujetos con trastornos de espectro autista con ansiedad y/o evitación social de moderada a severa. MX2024004766A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163271015P 2021-10-22 2021-10-22
PCT/US2022/078449 WO2023070045A1 (en) 2021-10-22 2022-10-20 Treatment of irritability in subjects with autism spectrum disorders with moderate to severe anxiety and/or social avoidance

Publications (1)

Publication Number Publication Date
MX2024004766A true MX2024004766A (es) 2024-06-11

Family

ID=84358575

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024004766A MX2024004766A (es) 2021-10-22 2022-10-20 Tratamiento de irritabilidad en sujetos con trastornos de espectro autista con ansiedad y/o evitación social de moderada a severa.

Country Status (10)

Country Link
US (1) US20240342198A1 (enExample)
EP (1) EP4419091A1 (enExample)
JP (1) JP2024536581A (enExample)
KR (1) KR20240093852A (enExample)
CN (1) CN118284412A (enExample)
AU (1) AU2022373753A1 (enExample)
CA (1) CA3235677A1 (enExample)
IL (1) IL312328A (enExample)
MX (1) MX2024004766A (enExample)
WO (1) WO2023070045A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3300266A1 (en) 2017-09-28 2026-03-02 Harmony Biosciences Management, Inc. Treatment of fragile x syndrome with cannabidiol
US12582664B2 (en) 2017-09-28 2026-03-24 Harmony Biosciences Management, Inc. Treatment of fragile x syndrome with cannabidiol

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8449908B2 (en) 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
CA2760460C (en) 2009-04-28 2019-04-02 Alltranz Inc. Transdermal formulations of cannabidiol comprising a penetration enhancer and methods of using the same
CA3300266A1 (en) * 2017-09-28 2026-03-02 Harmony Biosciences Management, Inc. Treatment of fragile x syndrome with cannabidiol
WO2019224824A1 (en) * 2018-05-24 2019-11-28 To Pharmaceuticals Llc Cannabis-based compositions for the treatment of autistic spectrum disorders
US20210369643A1 (en) * 2020-05-26 2021-12-02 Zynerba Pharmaceuticals, Inc. Treatment of fragile x syndrome and autism spectrum disorder with cannabidiol
BR112022026044A2 (pt) * 2020-06-29 2023-03-07 Zynerba Pharmaceuticals Inc Tratamento de síndrome do x frágil com canabidiol
WO2022103639A1 (en) * 2020-11-16 2022-05-19 Orcosa Inc. Methods of treating autoimmune or inflammatory conditions with cannabidiol or its derivatives/analogs

Also Published As

Publication number Publication date
JP2024536581A (ja) 2024-10-04
AU2022373753A1 (en) 2024-05-09
CN118284412A (zh) 2024-07-02
EP4419091A1 (en) 2024-08-28
IL312328A (en) 2024-06-01
WO2023070045A1 (en) 2023-04-27
KR20240093852A (ko) 2024-06-24
US20240342198A1 (en) 2024-10-17
CA3235677A1 (en) 2023-04-27

Similar Documents

Publication Publication Date Title
MX2024003145A (es) Tratamiento para el sindrome de supresion del 22q11.2 con cannabidiol.
MX2022014912A (es) Tratamiento del trastorno del espectro autista con cannabidiol.
Wu et al. Autism spectrum disorder (ASD): disturbance of the melatonin system and its implications
MX2022012424A (es) Tratamiento del sindrome del cromosoma x fragil con canabidiol.
Dear et al. Transdiagnostic versus disorder-specific and clinician-guided versus self-guided internet-delivered treatment for social anxiety disorder and comorbid disorders: a randomized controlled trial
MX2024004766A (es) Tratamiento de irritabilidad en sujetos con trastornos de espectro autista con ansiedad y/o evitación social de moderada a severa.
MX2022003193A (es) Tratamiento de encefalopatia asociada al gen syngap1.
RU2013136378A (ru) Применение фитоканнабиноида каннабидиола(cbd) в комбинации со стандартным противоэпилептическим стедством(saed) для лечения эпилепсии
NZ716627A (en) Methods of treating behavioral symptoms of neurological and mental disorders
PH12020551427A1 (en) Epinephrine spray formulations
WO2023009834A3 (en) Methods of treating cancer
EA201500996A1 (ru) Терапевтические применения эмпаглифлозина
TN2019000019A1 (en) Treatment and prevention of sleep disorders
NZ589228A (en) Combination of tetrahydrocannabinol (THC) and cannabidiol (CBD) for the treatment of a brain tumour
WO2009073544A3 (en) Methods for treating a disorder by regulating gprc6a
Winter et al. Remote cognitive behaviour therapy for social anxiety disorder: A meta-analysis
MX2024005002A (es) Métodos para tratar la endometriosis y otros trastornos ginecológicos no cancerosos con extracto de cáñamo.
MX2021013901A (es) Composiciones y métodos para el tratamiento del cáncer.
JOP20230125A1 (ar) كانابيديول لعلاج النوبات المستعصية على العلاج
MX2023014484A (es) Uso de roluperidona para tratar sintomas y trastornos negativos, aumentar la neuroplasticidad y promover la neuroproteccion.
JOP20220338A1 (ar) علاج متلازمة الكروموسوم إكس الهش باستخدام الكانابيديول
UA101035C2 (ru) Смягчающая композиция на основе вазелина, глицерина и вазелинового масла
MY197721A (en) Composition and uses thereof
MX2025013867A (es) Metodos para tratar el cancer en sujetos con exposicion previa a inhibidores de punto de control inmunitario
MX2023010115A (es) Tratamiento y/o reducción de la aparición de la migraña.